Evidence map›Paper›PMID 37692753›Full record

ReviewCureus2023

Chronic Recurrent Multifocal Osteomyelitis: A Comprehensive Literature Review.

Mariam Hassan, Heabah Assi, Maha Hassan, Jared J Bies, Swathi Prakash, Ali Hassan, Sara Alhariri, Fatma Dihowm

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Multiple primary bone lymphoma in children: a case description.Quantitative imaging in medicine and surgery · 2025
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Mariam HassanInternal Medicine, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso, USA.
Heabah AssiInternal Medicine, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso, USA.
Maha HassanBiomedical Sciences, Gulf Medical University, Ajman, ARE.
Jared J BiesInternal Medicine, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso, USA.
Swathi PrakashInternal Medicine, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso, USA.
Ali HassanEmergency Medicine, Mercy Health St. Elizabeth Boardman Hospital, Boardman, USA.
Sara AlhaririInternal Medicine, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso, USA.
Fatma DihowmInternal Medicine, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso, USA.
Texas Tech University · USGulf Medical University · AETexas Tech University Health Sciences Center · USAdvisory Board Company (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic recurrent multifocal osteomyelitis (CRMO) is a non-infectious, inflammatory disorder of the bones. CRMO typically affects children, with a predisposition to females. Bone-related pain is often felt in the metaphysis of long bones, particularly of the lower extremities, but it can also target other sites at varied time intervals. Patients are likely to complain of tenderness and swelling that may cause considerable disability and adversely impact quality of life. There are three main pathophysiological mechanisms that have been hypothesized to drive CRMO including imbalanced cytokine expression, increased inflammasome activation, and enhanced osteoclast differentiation. Therapies have been based on targeting and suppressing these key players in CRMO patients. The first step in management involves pain control. Non-steroidal anti-inflammatory drugs should provide initial relief, albeit temporarily. It is imperative to initiate immunosuppressive medication that will help limit bone involvement and thereby prevent the development of fractures or leg-length discrepancies, for example. The purpose of this literature review is to study the pathophysiology of CRMO and carefully dissect the agents that have been previously employed in the management of CRMO patients. This could allow for the purposeful formulation of individualized care plans and improving the overall well-being of patients. The authors included a multitude of PubMed-indexed articles published from 2000 onwards in this review.

Indexed as

aseptic inflammatory bone disorderbone painchronic recurrent multifocal osteomyelitisnoninfectious osteomyelitissystemic inflammation

Identifiers

PMID37692753
PMCPMC10483435
OpenAlexW4385660130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.